Vimarsana
Biggest News Aggregation in the World

Nancyu Lin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nancyu Lin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nancyu Lin Today - Breaking & Trending Today

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress - Vimarsana News

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23,...

Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer - Vimarsana News

Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer

Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer - Vimarsana News

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.

Clinical Challenges: Best Treatment Option for Breast Cancer Brain Metastases - Vimarsana News

Clinical Challenges: Best Treatment Option for Breast Cancer Brain Metastases

Surgery and RT aren't going anywhere while systemic therapy gains ground

Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Pati - Vimarsana News

Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Pati

– Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months of Follow-Up –BOTHELL, Wash.--(BUSINESS WIRE)--#SABCS2021--Seagen Inc. (Nasdaq:SGEN) today announced the presentation...